Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD32B monoclonal antibody BI-1607

A human immunoglobulin G1 (IgG1) monoclonal antibody targeting Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory- and antineoplastic-enhancing activities. Upon administration, anti-CD32B monoclonal antibody BI-1607 selectively targets and binds to CD32B, an inhibitory Fc gamma receptor (FcgR) protein expressed on immune cells, including macrophages. This prevents both the binding of human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2)-targeting monoclonal antibodies to CD32B, and CD32B-mediated inhibition of the activation of macrophages. By blocking CD32B, BI-1607 may enhance the activity of anti-HER2 monoclonal antibodies. CD32B, an inhibitory member of the FcgR family, is implicated in immune cell desensitization and tumor cell resistance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FcgRIIB monoclonal antibody BI-1607
Code name:BI 1607
BI-1607
BI1607
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search